# Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

> **NCT00466752** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 5 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Stage II Prostate Cancer
- Stage III Prostate Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **GENETIC:** microarray analysis
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** gene expression analysis
- **PROCEDURE:** needle biopsy
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** western blotting
- **GENETIC:** RNA analysis

## Key facts

- **NCT ID:** NCT00466752
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-04
- **Final completion:** 2011-07-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466752, "Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00466752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*